Sitagliptin Mitigates Doxorubicin-Induced Cardiac Toxicity in Rats, Targeting TLR4/NF-Kb Signaling Pathway | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 14, Volume 99, Issue 1, April 2025, Page 1445-1450 PDF (705.48 K) | ||||
| DOI: 10.21608/ejhm.2025.421224 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: The emergence of toxicities to vital organs, including the heart, has limited the use of the broad-spectrum antitumor drug doxorubicin (DOX). Sitagliptin (STG) offers a number of defensive advantages. Objective: This study aimed to illustrate the possible underlying processes and cardioprotective impact of STG in cardiotoxicity caused by DOX. Material and methods: DOX, DOX+STG, and control (10/group) were the three groups into which thirty male albino rats were divided. Cardiac index, serum cTnI, serum LDH, serum CK-MB, cardiac MDA, cardiac SOD, cardiac TNF-α, cardiac IL-6, cardiac IL-10, cardiac NF-kB gene expression and cardiac TLR4 gene expression. Furthermore, immunohistochemical and cardiac histology studies were carried out. Results: There was dramatically elevated serum cTnI, serum LDH, serum CK-MB, cardiac MDA, cardiac TNF-α, cardiac IL-6 in addition to cardiac NF-kB and cardiac TLR4 immunoreaction and gene expression with substantial decline in cardiac index value, cardiac SOD and cardiac IL-10 of DOX group compared to control. STG dramatically ameliorated DOX induced cardiac changes. Conclusion: STG offered cardioprotection in DOX induced cardiotoxicity by downregulating the cardiac TLR4/NF-kB pathway, anti-inflammatory and antioxidant functions. | ||||
| Keywords | ||||
| Doxorubicin; NF-kB; Cardiotoxicity; Sitaglibtin; TLR4 | ||||
|
Statistics Article View: 289 PDF Download: 151 |
||||
